Search the web
Welcome, Guest
[Sign Out, My Account]

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
PPHM > SEC Filings for PPHM > Form 8-K on 8-May-2014All Recent SEC Filings




Change in Directors or Principal Officers

Item 5.02 Departure Of Directors Or Certain Officers; Election Of Directors;
Appointment Of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 6, 2014, the Compensation Committee of the Board of Directors ("Committee") of Peregrine Pharmaceuticals, Inc. (the "Company"), approved a broad based annual grant of stock options ("Grants") for fiscal year 2015 to substantially all of the Company's employees, the Company's three non-employee directors and two consultants to purchase an aggregate of 3,995,804 shares of common stock. The Grants will be from the Company's 2011 Stock Incentive Plan and will be evidenced by and subject to the terms of a Stock Option Agreement. Included as recipients of the Grants are the following named executive officers:

                                                                  Number of Shares
Named Executive Officer          Title                     Underlying Stock Option Grants
Steven W. King          President and Chief Executive                 400,000
Paul J. Lytle           Chief Financial Officer                       200,000
Mark R. Ziebell         V.P., General Counsel                         175,000
Shelley P.M. Fussey     V.P., Intellectual Property                   100,000
Joseph S. Shan          V.P., Clinical & Regulatory                   100,000

In determining the number of shares of common stock covered by the Grants to the named executive officers, the Committee reviewed a report prepared by an independent compensation consulting firm which established proposed grant guidelines at a long-term incentive value ("LTI Value") for equity based awards at the fiftieth percentile of the Company's peer group to ensure that the Company's stock option granting practices for named executive officers and other employees were aligned with competitive norms. The LTI Value of the Grants to named executive officers were below the fiftieth percentile of LTI Value of the Company's peer group as set forth in the report prepared by the independent compensation consulting firm.

The Committee has determined that the exercise price of the Grants will be equal to the closing price of the Company's common stock on May 6, 2014, the date of grant, and shall vest quarterly in equal installments over a two year period.

  Add PPHM to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for PPHM - All Recent SEC Filings
Copyright © 2015 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.